JPH01503537A - β‐ラクタミン類の効果を減少させるための、経口投与可能な治療用組成物 - Google Patents

β‐ラクタミン類の効果を減少させるための、経口投与可能な治療用組成物

Info

Publication number: JPH01503537A
Authority: JP; Japan
Prior art keywords: lactamase; bacteria; bacteroides; producing; composition according
Prior art date: 1987-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP63503346A

Other languages

English (en)

Japanese (ja)

Inventor

タンクルド・シリル

アンドルモン・アントワーヌ

ラビア・ロジエ

レオナルド・フローレンス

Original Assignee

アンステイテユー・ギユスタブ・ルシイ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-04-10

Filing date

1988-04-08

Publication date

1989-11-30

1988-04-08 Application filed by アンステイテユー・ギユスタブ・ルシイ filed Critical アンステイテユー・ギユスタブ・ルシイ

1989-11-30 Publication of JPH01503537A publication Critical patent/JPH01503537A/ja

Status Pending legal-status Critical Current

Links

230000000694 effects Effects 0.000 title claims description 18
239000000203 mixture Substances 0.000 title claims description 17
230000001225 therapeutic effect Effects 0.000 title claims description 7
108090000204 Dipeptidase 1 Proteins 0.000 claims description 17
102000006635 beta-lactamase Human genes 0.000 claims description 17
241000894006 Bacteria Species 0.000 claims description 14
241000606125 Bacteroides Species 0.000 claims description 10
230000000968 intestinal effect Effects 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 5
230000001717 pathogenic effect Effects 0.000 claims description 4
241000193403 Clostridium Species 0.000 claims description 3
CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 3
229960003866 cefaloridine Drugs 0.000 claims description 3
241001148471 unidentified anaerobic bacterium Species 0.000 claims description 3
241000606219 Bacteroides uniformis Species 0.000 claims description 2
150000003952 β-lactams Chemical class 0.000 claims description 2
108010077805 Bacterial Proteins Proteins 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 8
238000011282 treatment Methods 0.000 description 8
229960003022 amoxicillin Drugs 0.000 description 5
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 5
244000005700 microbiome Species 0.000 description 5
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 5
238000012360 testing method Methods 0.000 description 5
239000002253 acid Substances 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
238000000034 method Methods 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
241001135261 Prevotella oralis Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
PPRCPJNOUHNSOE-UHFFFAOYSA-N Amurolin Natural products C1=2C3=C(O)C(OC)=CC=2CCNC1CC13CCC(O)CC1 PPRCPJNOUHNSOE-UHFFFAOYSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000606124 Bacteroides fragilis Species 0.000 description 1
240000008574 Capsicum frutescens Species 0.000 description 1
241000193171 Clostridium butyricum Species 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000605986 Fusobacterium nucleatum Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
241001135215 Prevotella bivia Species 0.000 description 1
241001135219 Prevotella disiens Species 0.000 description 1
241001135221 Prevotella intermedia Species 0.000 description 1
241001135223 Prevotella melaninogenica Species 0.000 description 1
241000605860 Prevotella ruminicola Species 0.000 description 1
241001528479 Pseudoflavonifractor capillosus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000033702 Sthenelanella uniformis Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
229960003669 carbenicillin Drugs 0.000 description 1
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
229960003012 cefamandole Drugs 0.000 description 1
229960001139 cefazolin Drugs 0.000 description 1
MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
229960000484 ceftazidime Drugs 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
229960003326 cloxacillin Drugs 0.000 description 1
LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical group N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
230000010006 flight Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
244000005709 gut microbiome Species 0.000 description 1
244000005702 human microbiome Species 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940116108 lactase Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940041009 monobactams Drugs 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical group N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
229960001019 oxacillin Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
238000000053 physical method Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
229940046307 sodium thioglycolate Drugs 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229960001114 temocillin Drugs 0.000 description 1
BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
229960004659 ticarcillin Drugs 0.000 description 1
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
108010042582 tosylarginine methyl ester hydrolase Proteins 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP63503346A 1987-04-10 1988-04-08 β‐ラクタミン類の効果を減少させるための、経口投与可能な治療用組成物 Pending JPH01503537A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8705110A FR2613624B1 (fr)	1987-04-10	1987-04-10	Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
FR87/05110		1987-04-10

Publications (1)

Publication Number	Publication Date
JPH01503537A true JPH01503537A (ja)	1989-11-30

Family

ID=9350003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP63503346A Pending JPH01503537A (ja)	1987-04-10	1988-04-08	β‐ラクタミン類の効果を減少させるための、経口投与可能な治療用組成物

Country Status (8)

Country	Link
EP (1)	EP0309532A1 (fr)
JP (1)	JPH01503537A (fr)
AU (1)	AU604117B2 (fr)
FR (1)	FR2613624B1 (fr)
OA (1)	OA09023A (fr)
PT (1)	PT87190B (fr)
WO (1)	WO1988007865A1 (fr)
ZA (1)	ZA882426B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI920206A0 (fi) *	1992-01-17	1992-01-17	Pekka Untamo Heino	Medicinsk anvaendning, medicinskt foerfarande och preparat.
FR2843302B1 (fr) *	2002-08-09	2004-10-22	Centre Nat Rech Scient	Forme galenique pour la delivrance colique de principes actifs
US8273376B2 (en)	2006-11-17	2012-09-25	Da Volterra	Colonic delivery of metallo-dependent enzymes
FI20105572A0 (fi)	2010-05-24	2010-05-24	Prevab R Lcc	Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
GB201117313D0 (en)	2011-10-07	2011-11-16	Gt Biolog Ltd	Bacterium for use in medicine
GB201306536D0 (en)	2013-04-10	2013-05-22	Gt Biolog Ltd	Polypeptide and immune modulation
BR112016023360B1 (pt)	2014-04-17	2023-03-07	Synthetic Biologics, Inc	Beta-lactamase e seu uso
JP6803328B2 (ja)	2014-08-28	2021-01-06	シンセティックバイオロジクス，インコーポレイテッド	大腸菌ベースでのベータラクタマーゼ生産
WO2016057744A1 (fr)	2014-10-08	2016-04-14	Synthetic Biologics, Inc.	Formulations de bêta-lactamase et utilisations de celles-ci
EP3236993B1 (fr)	2014-12-23	2023-09-13	Theriva Biologics, Inc.	Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux
EP3400953A1 (fr)	2014-12-23	2018-11-14	4D Pharma Research Limited	Polypeptide pirin et modulation immunitaire
AR103260A1 (es)	2014-12-23	2017-04-26	4D Pharma Res Ltd	Modulación inmunitaria
EP3261662B1 (fr)	2015-02-23	2021-07-21	Synthetic Biologics Inc.	Carbapénémases à utiliser avec des antibiotiques pour la protection du microbiome intestinal
EP3265119B1 (fr)	2015-03-06	2023-10-11	Theriva Biologics, Inc.	Dosage de beta-lactamase sûr et efficace pour la protection du microbiome
WO2016203221A1 (fr)	2015-06-15	2016-12-22	4D Pharma Research Limited	Compositions comprenant des souches bactériennes
NZ737752A (en)	2015-06-15	2022-02-25	4D Pharma Res Ltd	Compositions comprising bacterial strains
MA41010B1 (fr)	2015-06-15	2020-01-31	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
SMT201900588T1 (it)	2015-06-15	2019-11-13	4D Pharma Res Limited	Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41060B1 (fr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
CN108513545B (zh)	2015-11-20	2020-11-03	4D制药研究有限公司	包含细菌菌株的组合物
GB201520497D0 (en)	2015-11-20	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
ME03487B (fr)	2016-03-04	2020-01-20	4D Pharma Plc	Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
GB201612191D0 (en)	2016-07-13	2016-08-24	4D Pharma Plc	Compositions comprising bacterial strains
TWI802545B (zh)	2016-07-13	2023-05-21	英商４Ｄ製藥有限公司	包含細菌菌株之組合物
GB201621123D0 (en)	2016-12-12	2017-01-25	4D Pharma Plc	Compositions comprising bacterial strains
DK3630136T3 (da)	2017-05-22	2021-05-25	4D Pharma Res Ltd	Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (fr)	2017-05-24	2022-11-30	4D Pharma Research Limited	Compositions comprenant des souches bactériennes
CA3066189A1 (fr)	2017-06-14	2018-12-20	4D Pharma Research Limited	Compositions comprenant des souches bacteriennes
SMT202000555T1 (it)	2017-06-14	2020-11-10	4D Pharma Res Limited	Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it)	2017-06-14	2021-01-05	4D Pharma Res Limited	Composizioni comprendenti ceppi batterici

1987
- 1987-04-10 FR FR8705110A patent/FR2613624B1/fr not_active Expired - Lifetime
1988
- 1988-04-07 ZA ZA882426A patent/ZA882426B/xx unknown
- 1988-04-08 JP JP63503346A patent/JPH01503537A/ja active Pending
- 1988-04-08 WO PCT/FR1988/000172 patent/WO1988007865A1/fr not_active Ceased
- 1988-04-08 PT PT87190A patent/PT87190B/pt not_active IP Right Cessation
- 1988-04-08 AU AU15786/88A patent/AU604117B2/en not_active Ceased
- 1988-04-08 EP EP88903277A patent/EP0309532A1/fr not_active Withdrawn
- 1988-12-09 OA OA59487A patent/OA09023A/fr unknown

Also Published As

Publication number	Publication date
OA09023A (fr)	1991-03-31
PT87190A (pt)	1988-05-01
EP0309532A1 (fr)	1989-04-05
PT87190B (pt)	1992-08-31
WO1988007865A1 (fr)	1988-10-20
FR2613624A1 (fr)	1988-10-14
ZA882426B (en)	1988-09-28
AU604117B2 (en)	1990-12-06
AU1578688A (en)	1988-11-04
FR2613624B1 (fr)	1990-11-23

Publication	Publication Date	Title
JPH01503537A (ja)	1989-11-30	β‐ラクタミン類の効果を減少させるための、経口投与可能な治療用組成物
Jia et al.	2022	Melatonin prevents conjugative transfer of plasmid-mediated antibiotic resistance genes by disrupting proton motive force
Schmidt et al.	1979	Vibrio alginolyticus infections in humans
US6849256B1 (en)	2005-02-01	Inhibition of pathogens by probiotic bacteria
Baquero et al.	2007	The antibiotic selective process: Concentration‐specific amplification of low‐level resistant populations
Van der Waaij	1987	Colonization resistance of the digestive tract—mechanism and clinical consequences
JP2014001245A (ja)	2014-01-09	Ｂａｃｉｌｌｕｓｃｏａｇｕｌａｎｓによる病原体の阻害
EP4009995B1 (fr)	2024-10-16	Mélange probiotique
JPH0413628A (ja)	1992-01-17	クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
Harris	1988	Subperiosteal inflammation of the orbit: a bacteriological analysis of 17 cases
Woodruff et al.	1977	Fosfomycin: Laboratory studies.
Abdel-Haq et al.	2006	Antibiotic susceptibilities of Yersinia enterocolitica recovered from children over a 12-year period
Preston et al.	1994	Antimicrobial susceptibility of pathogenic Yersinia enterocolitica isolated in Canada from 1972 to 1990
Barker et al.	1972	Characteristics of some co-trimoxazole-resistant Enterobacteriaceae from infected patients
CA2573494A1 (fr)	2006-01-26	Gestion de la formation d'un biofilm
EP0768376B1 (fr)	2004-05-06	Milieux sélectifs de culture et d'isolement des bactéries Gram, composition antibiotique
Brook et al.	1995	In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule
Fast et al.	1983	Treatment of chancroid. A comparison of sulphamethoxazole and trimethoprim-sulphamethoxazole.
Neilands	1979	The ironic function of bacteriophage receptors
TW202008993A (zh)	2020-03-01	芽孢乳酸菌用於製備代謝重金屬及保護肝臟醫藥組成物之用途
Robins-Browne, RM, Jacbos, MR, Koornhof, HJ & Mauff	1979	Yersinia enterocolitica biotype 1 in South Africa
Nivetha et al.	2025	Restraint of dental caries–inducing Streptococcus mutans MTCC497 by potential oral bacterial metabolite–In vitro and In vivo analysis in Caenorhabditis elegans
Feldman	1973	Effects of trimethoprim and sulfisoxazole, alone and in combination, on growth and carriage of Neisseria meningitidis
Ghafghaichi et al.	2010	Mixed infection involving Actinomyces, Aggregatibacter, and Fusobacterium species presenting as perispinal tumor
Drow et al.	1984	Splenic abscess caused by Shigella flexneri and Bacteroides fragilis